<DOC>
	<DOCNO>NCT02765997</DOCNO>
	<brief_summary>This open label , interventional , randomized phase II trial compare StemRegenin-1 ( SR-1 ) culture umbilical cord blood ( experimental arm ) unmanipulated umbilical cord blood ( standard care arm ) transplantation myeloablative CY/FLU/TBI conditioning . A 2:1 randomization employ high chance assign experimental arm .</brief_summary>
	<brief_title>StemRegenin-1 Expanded v Unexpanded UCB High Risk Heme Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Must partially HLA match UCB unit precryopreserved TNC dose &gt; 2.5 x 107 per kilogram recipient weight . HLA match initially base 4 6 HLAA B ( low intermediate resolution molecular typing ) DRB1 ( high resolution molecular typing ) . Eligible Diseases Acute myelogenous leukemia ( AML ) follow stage : Intermediate high risk leukemia first complete remission ( CR1 ) base institutional criterion . Any second subsequent CR . Secondary AML prior malignancy remission least 12 month . Acute lymphocytic leukemia ( ALL ) follow stage : High risk first remission . 1 . Ph+ ALL , 2 . MLL rearrangement slow early response Day 14 , 3 . Hypodiploidy ( &lt; 44 chromosome DNA index &lt; 0.81 ) , 4 . End induction M3 bone marrow , 5 . End induction M2 M23 Day 42 . High risk second CR base institutional criterion ( eg , child , bone marrow relapse &lt; 36 month induction Tlineage bone marrow relapse early isolated central nervous system ( CNS ) relapse &lt; 6 month diagnosis , slow reinduction ( stage M23 day 28 induction ) regardless length remission . Any third subsequent CR . Biphenotypic/undifferentiated leukemia CR Chronic myelogenous leukemia ( CML ) exclude refractory blast crisis Myelodysplasia ( MDS ) IPSS Int2 High risk ( i.e . RAEB , RAEBt ) refractory anemia Other Inclusion Criteria Karnofsky score &gt; 70 % ( 16 year old ) Lansky play score &gt; 70 ( child &lt; 16 year ) appendix II Adequate organ function define : Renal : Serum creatinine within normal range age , serum creatinine outside normal range age , renal function ( creatinine clearance GFR ) &gt; 70 mL/min/1.73 m2 . Hepatic : Bilirubin â‰¤2.5 x mg/dL ; AST , ALT , alkaline phosphatase &lt; 5 x upper limit normal , Pulmonary function : DLCO , FEV1 , FEC ( diffusion capacity ) &gt; 50 % predict ( correct hemoglobin ) ; unable perform pulmonary function test , normal O2 saturation room air . Cardiac : Left ventricular ejection fraction rest must &gt; 45 % Available 'backup ' HSPC graft ( e.g , second partially HLA match UCB unit , haploidentical relate donor ) . Voluntary write consent sign ( adult parental ) performance studyrelated procedure part normal medical care Pregnant breast feeding . The agent use study may teratogenic fetus information excretion agent breast milk . Females childbearing potential must blood test urine study within 14 day prior study enrollment rule pregnancy . Evidence human immunodeficiency virus ( HIV ) infection know HIV positive serology . Active bacterial , viral fungal infection ( currently take medication progression clinical symptom ) . Prior autologous allogeneic transplant within past 12 month . Other active malignancy . Inability receive TBI 1320 cGy ( e.g. , extensive prior therapy include &gt; 12 month alkylator therapy &gt; 6 month alkylator therapy extensive radiation . Or prior Y90 ibritumomab ( Zevalin ) I131 tostumomab ( Bexxar ) , part salvage therapy .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>MDS</keyword>
</DOC>